Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Urine Test Rapidly Predicts Smokers' Lung Cancer Risk

By LabMedica International staff writers
Posted on 27 Apr 2009
Scientists have found that smokers with the highest urine levels of two tobacco metabolites have a higher risk of developing lung cancer. More...
This might explain why some smokers get lung cancer while others do not.

Smokers with the highest urine levels of the tobacco metabolite called 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) had a two-fold increased risk of developing lung cancer than those with the lowest levels. When a second metabolite called cotinine was included in the analysis, the investigators found that those smokers with the highest levels of both NNAL and cotinine in their urine were 8.5 times more likely to develop the disease.

The study was conducted by Dr. Jian-Min Yuan, associate professor of public health at the University of Minnesota (Minneapolis, MN, USA) and colleagues. Professor Yuan said although we know that smoking leads to lung cancer, there are over 60 potential cancer causing chemicals in tobacco smoke, and "the more accurately we can identify the culprit, the better we will become at predicting risk." He added, "If we can identify a smoker with a high level of metabolites, and down the road they have a higher risk of lung cancer, public health workers can get them motivated to quit smoking."

Prof. Yuan said that a standard urine metabolite test for smokers would probably cost $100 to $120 and take a few years to develop.

According to the World Health Organization (WHO; Geneva, Switzerland) lung cancer is the most common cancer worldwide, accounting for 1.2 million new cases annually. It is also the biggest cause of death by cancer, responsible for 17.8 % of all cancer deaths.

The study was presented at the 100th Annual Meeting of the American Association for Cancer Research, which took place from April 18-22, 2009 at the Colorado Convention Center in Denver (CO, USA).

Related Links:

University of Minnesota
World Health Organization



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.